The National Medicines Safety Agency (Ansm) is currently reassessing the benefit / risk ratio of Diane 35 *. The examination of this anti-acne should be completed “in a very short time”, announced the director of Ansm during the press conference held this Friday by Marisol Touraine. In 85% of cases, this product is prescribed as a contraceptive, that is to say outside the framework of its marketing authorization. Without prejudging the results of this new expertise, Dominique Maraninchi judged “abnormal to leave an ambiguity on a health product”.
.
